Developing apoferritin into an imaging and drug delivery platform; Optimisation of production and efficiency of cell uptake
Lead Research Organisation:
University of Nottingham
Department Name: Sch of Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Neil Thomas (Primary Supervisor) |
 http://orcid.org/0000-0002-9260-5423
|
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| BB/M008770/1 | 30/09/2015 | 31/03/2024 | |||
| 1803018 | Studentship | BB/M008770/1 | 30/09/2016 | 17/03/2021 |
| Description | I have modified a protein nanocage to allow potential encapsulation of small proteins within the cage, for the potential use of peptides in cancer therapeutics. Additionally, I have modified the protein cage, to prevent the endocytosis of apoferritin. This was done to eliminate endocytosis of apoferritin via the transferrin receptor and confirm that apoferritin is only endocytosed via cancer receptor targets on apoferritins exterior. |
| Exploitation Route | 1. Could be used to target cancer cells via peptides. |
| Sectors | Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |